Corvus Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.88 Insider Own0.10% Shs Outstand46.55M Perf Week-3.76%
Market Cap43.30M Forward P/E- EPS next Y-0.53 Insider Trans123.16% Shs Float41.55M Perf Month1.79%
Income-40.70M PEG- EPS next Q-0.22 Inst Own47.80% Short Float / Ratio0.50% / 1.38 Perf Quarter-10.64%
Sales- P/S- EPS this Y-408.00% Inst Trans-12.99% Short Interest0.21M Perf Half Y-18.91%
Book/sh1.39 P/B0.63 EPS next Y41.10% ROA-42.50% Target Price3.38 Perf Year-74.32%
Cash/sh1.00 P/C0.87 EPS next 5Y- ROE-49.10% 52W Range0.69 - 3.64 Perf YTD-63.66%
Dividend- P/FCF- EPS past 5Y15.20% ROI- 52W High-75.94% Beta0.97
Dividend %- Quick Ratio3.70 Sales past 5Y- Gross Margin- 52W Low26.01% ATR0.07
Employees28 Current Ratio3.70 Sales Q/Q- Oper. Margin- RSI (14)49.14 Volatility7.65% 8.21%
OptionableYes Debt/Eq0.00 EPS Q/Q-31.20% Profit Margin- Rel Volume0.12 Prev Close0.89
ShortableYes LT Debt/Eq0.00 EarningsNov 03 AMC Payout- Avg Volume148.96K Price0.88
Recom2.00 SMA200.87% SMA501.67% SMA200-24.27% Volume18,451 Change-2.12%
Dec-01-21Resumed Jefferies Buy $8
May-27-21Initiated Cantor Fitzgerald Overweight $10
Feb-10-21Downgrade Mizuho Buy → Neutral $7 → $4
Sep-12-19Initiated Mizuho Buy
May-29-19Initiated ROTH Capital Buy $6
Aug-24-17Upgrade Credit Suisse Underperform → Neutral
May-01-17Downgrade Credit Suisse Neutral → Underperform
Apr-18-16Initiated Guggenheim Buy
Apr-18-16Initiated Credit Suisse Outperform
Nov-14-22 08:30AM
Nov-03-22 04:05PM
Oct-27-22 04:05PM
Oct-25-22 04:05PM
09:55AM Loading…
Oct-14-22 09:55AM
Oct-04-22 01:15PM
Sep-27-22 08:51AM
Sep-26-22 04:05PM
Sep-06-22 04:05PM
Aug-26-22 06:13AM
Aug-11-22 12:00PM
Aug-08-22 04:05PM
Jul-28-22 04:05PM
Jul-21-22 04:05PM
07:30AM Loading…
May-10-22 07:30AM
May-07-22 09:43AM
May-05-22 04:05PM
Apr-26-22 07:30AM
Mar-19-22 08:06AM
Mar-10-22 04:05PM
Mar-03-22 04:30PM
Jan-13-22 06:30PM
Jan-01-22 07:43AM
Dec-13-21 09:00AM
Nov-12-21 07:00AM
Nov-10-21 04:05PM
Nov-02-21 04:05PM
Nov-01-21 04:05PM
04:05PM Loading…
Oct-27-21 04:05PM
Oct-25-21 07:30PM
Sep-29-21 07:11AM
Sep-28-21 02:30PM
Sep-27-21 10:08AM
Sep-24-21 03:54PM
Sep-22-21 03:45PM
Sep-20-21 08:14AM
Sep-17-21 12:28PM
Sep-16-21 11:03AM
Sep-15-21 11:40AM
Sep-14-21 09:18AM
Sep-13-21 11:35AM
Sep-07-21 04:05PM
Sep-03-21 08:25AM
Sep-02-21 10:11AM
Aug-24-21 10:18AM
Aug-17-21 08:28AM
Aug-16-21 05:00PM
Aug-05-21 10:00AM
Aug-02-21 04:05PM
Jul-20-21 10:00AM
Jul-16-21 07:02AM
Jul-15-21 04:05PM
May-25-21 04:05PM
May-08-21 03:28AM
May-05-21 09:00AM
Apr-29-21 04:05PM
Apr-20-21 02:51AM
Mar-25-21 08:30AM
Mar-05-21 08:30AM
Feb-18-21 11:38PM
Feb-17-21 04:10PM
Feb-12-21 09:00AM
Feb-11-21 04:01PM
Feb-04-21 09:57AM
Jan-30-21 02:53AM
Dec-07-20 03:28PM
Dec-06-20 10:00AM
Nov-30-20 08:00AM
Nov-11-20 04:05PM
Nov-09-20 08:05AM
Nov-02-20 08:00AM
Nov-01-20 09:08AM
Oct-29-20 04:00PM
Oct-07-20 10:39AM
Oct-05-20 09:57AM
Sep-17-20 03:01AM
Sep-11-20 08:30AM
Sep-10-20 08:30AM
Sep-08-20 06:02PM
Aug-04-20 04:05PM
Aug-03-20 11:33AM
Jul-30-20 04:02PM
Jul-23-20 08:30AM
Jul-20-20 03:30PM
Jul-09-20 08:43AM
Jul-08-20 10:22AM
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MILLER RICHARD A MDPresident and CEOSep 28Buy0.7625,00019,0701,394,405Sep 28 05:45 PM
MILLER RICHARD A MDPresident and CEOSep 20Buy0.8120,00016,2531,369,405Sep 20 06:58 PM
MILLER RICHARD A MDPresident and CEOJun 27Buy1.005,0004,9841,349,405Jun 28 07:15 PM
MILLER RICHARD A MDPresident and CEOJun 24Buy1.035,0005,1501,344,405Jun 28 07:15 PM
MILLER RICHARD A MDPresident and CEOJun 06Buy1.018908991,339,405Jun 06 06:43 PM
MILLER RICHARD A MDPresident and CEOJun 02Buy0.985,0004,8981,338,515Jun 06 06:43 PM
MILLER RICHARD A MDPresident and CEOMar 31Buy1.6415,00024,5341,333,515Apr 01 04:18 PM
MILLER RICHARD A MDPresident and CEOMar 17Buy1.595,0007,9501,318,515Mar 17 07:09 PM
LEA LEIVChief Financial OfficerMar 17Buy1.6513,87822,89999,238Mar 17 07:10 PM
LEA LEIVChief Financial OfficerMar 16Buy1.5435,16054,14685,360Mar 17 07:10 PM
MILLER RICHARD A MDPresident and CEOMar 15Buy1.4725,00036,6501,313,515Mar 17 07:09 PM